NCT02718716

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.

Conditions

• Thrombocytopenia

Interventions

Type	Name	Description
DRUG	UCB7665	* Intervention Type: Biological/Vaccine * Pharmaceutical Form: Powder for solution for infusion * Concentration: 100 mg/ml - Route of Administration: Subcutaneous infusion

Timeline

• Start date: 2016-03-02
• Primary completion: 2019-02-04
• Completion: 2019-02-04
• First posted: 2016-03-24
• Last updated: 2024-01-29
• Results posted: 2024-01-29

Locations

29 sites across 11 countries: Australia, Bulgaria, Czechia, Georgia, Germany, Italy, Moldova, Poland, Romania, Spain, United Kingdom